Propanc Biopharma Inc. has announced the submission of a request for a foreign filing license from Spain for two provisional patents describing new methods to treat resistant cancer and fibrosis. These discoveries, resulting from a joint research and drug discovery program with the Universities of Jaén and Granada in Spain, will be filed with IP Australia and are expected to be submitted in key global jurisdictions in the future. The company also revealed plans for a Phase 1b, First-In-Human study of its lead product candidate, PRP, in 2026, which will help define its therapeutic dose and explore its applications across multiple disease conditions. The patents represent a significant expansion of Propanc's intellectual property portfolio, especially as they detail the use of PRP for chronic diseases beyond cancer, such as fibrosis. The scientific results themselves have not yet been presented, as further studies are planned.